We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Extends BLA Review for Regeneron’s COVID-19 Antibody Cocktail
FDA Extends BLA Review for Regeneron’s COVID-19 Antibody Cocktail
The FDA has extended by three months its review of Regeneron Pharmaceuticals’ Biologics License Application (BLA) for its antiviral drug REGEN-COV (casirivimab plus imdevimab) for full approval as a preventive treatment for COVID-19.